[
{
"symbol" : "GLPG",
"exchange" : "AMS",
"id": "699286",
"t" : "GLPG",
"e" : "AMS",
"name" : "Galapagos NV"
, "f_reuters_url" : "http:\u002F\u002Fstocks.us.reuters.com\u002Fstocks\u002Fratios.asp?rpc=66\u0026symbol=GLPG.AS",
"f_recent_quarter_date" : "",
"f_annual_date" : "",
"f_ttm_date" : "",
"financials" :
[{
"f_type" : "Income\u0026nbsp\u003BStatement"
,"url" : "http://www.google.com/finance?fstype=ii&q=AMS:GLPG"
,"f_figures" :
[
]
},
{
"f_type" : "Balance\u0026nbsp\u003BSheet"
,"url" : "http://www.google.com/finance?fstype=bi&q=AMS:GLPG"
,"f_figures" :
[
]
},
{
"f_type" : "Cash\u0026nbsp\u003BFlow"
,"url" : "http://www.google.com/finance?fstype=ci&q=AMS:GLPG"
,"f_figures" :
[
]
}],
"kr_recent_quarter_date" : "Q3 (Sep \u002717)",
"kr_annual_date" : "2016",
"kr_ttm_date" : "TTM",
"keyratios" :
[
{
"title" : "Net profit margin",
"recent_quarter" : "-109.85%",
"annual" : "35.62%",
"ttm" : "-20.69%"
},
{
"title" : "Operating margin",
"recent_quarter" : "-88.97%",
"annual" : "-7.58%",
"ttm" : "-13.25%"
},
{
"title" : "EBITD margin",
"recent_quarter" : "",
"annual" : "-4.82%",
"ttm" : "-11.01%"
},
{
"title" : "Return on average assets",
"recent_quarter" : "-10.88%",
"annual" : "7.08%",
"ttm" : "-3.36%"
},
{
"title" : "Return on average equity",
"recent_quarter" : "-13.94%",
"annual" : "9.61%",
"ttm" : "-4.57%"
},
{
"title" : "Employees",
"recent_quarter" : "578",
"annual" : "-",
"ttm" : "-"
}
]
, "c" : "+1.18",
"l" : "93.24",
"cp" : "1.28",
"ccol" : "chg",
"op" : "93.06",
"hi" : "94.34",
"lo" : "92.56",
"vo" : "574,924.00",
"avvo" : "526,455.00",
"hi52" : "94.36",
"lo52" : "59.13",
"mc" : "4.75B",
"pe" : "",
"fwpe" : "",
"beta" : "",
"eps" : "-0.77",
"dy" : "",
"ldiv" : "",
"shares" : "50.90M",
"instown" : "",
"eo":""
, "related" : [
{
"id" : "699286",
"name" : "Galapagos NV",
"t" : "GLPG",
"e" : "AMS",
"l" : "93.24",
"c" : "+1.18",
"mc" : "4.75B",
"cp" : "1.28",
"ccol" : "chg"
}
,
{
"id" : "706869",
"name" : "ThromboGenics NV",
"t" : "THR",
"e" : "EBR",
"l" : "4.39",
"c" : "-0.02",
"mc" : "158.45M",
"cp" : "-0.45",
"ccol" : "chr"
}
,
{
"id" : "670686",
"name" : "MorphoSys AG",
"t" : "MOR",
"e" : "ETR",
"l" : "83.95",
"c" : "+1.90",
"mc" : "2.47B",
"cp" : "2.32",
"ccol" : "chg"
}
,
{
"id" : "667523",
"name" : "UCB SA",
"t" : "UCB",
"e" : "EBR",
"l" : "69.56",
"c" : "+0.60",
"mc" : "13.53B",
"cp" : "0.87",
"ccol" : "chg"
}
,
{
"id" : "719971",
"name" : "Ablynx NV",
"t" : "ABLX",
"e" : "EBR",
"l" : "35.50",
"c" : "-0.16",
"mc" : "2.65B",
"cp" : "-0.45",
"ccol" : "chr"
}
,
{
"id" : "670560",
"name" : "Evotec AG",
"t" : "EVT",
"e" : "ETR",
"l" : "14.64",
"c" : "+0.16",
"mc" : "2.16B",
"cp" : "1.14",
"ccol" : "chg"
}
,
{
"id" : "706199",
"name" : "MDxHealth SA",
"t" : "MDXH",
"e" : "EBR",
"l" : "3.89",
"c" : "+0.01",
"mc" : "193.92M",
"cp" : "0.26",
"ccol" : "chg"
}
,
{
"id" : "667570",
"name" : "Merck KGaA",
"t" : "MRK",
"e" : "ETR",
"l" : "91.12",
"c" : "+1.16",
"mc" : "11.78B",
"cp" : "1.29",
"ccol" : "chg"
}
,
{
"id" : "715096",
"name" : "Tigenix NV",
"t" : "TIG",
"e" : "EBR",
"l" : "1.71",
"c" : "-0.01",
"mc" : "468.48M",
"cp" : "-0.47",
"ccol" : "chr"
}
,
{
"id" : "9233882",
"name" : "QUESTCOR PHARMACEUT.",
"t" : "QPH",
"e" : "FRA",
"l" : "68.71",
"c" : "",
"mc" : "",
"cp" : "",
"ccol" : ""
}
,
{
"id" : "12556180",
"name" : "Roche Holding AG",
"c" : "",
"mc" : "",
"cp" : "",
"ccol" : ""
}
]
, "summary" : [{
"address": "Generaal De Wittelaan 3, MALINES (MECHELEN), 2800, Belgium",
"phone": "+32-15-342900",
"fax": "+32-15-342901",
"url": "http:\u002F\u002Fwww.glpg.com",
"overview" : "Galapagos NV is a Belgium-based biotechnology company. The Company\u0027s activities are divided into two operating divisions: Research and Development (R \u0026 D) and Services. The R \u0026 D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International."
} ]
, "management" : [
{
"name" : "Onno van de Stolpe",
"age" : "58",
"title" : "Chief Executive Officer, Executive Director, Member of the Executive Committee"
}
,
{
"name" : "Bart Filius",
"title" : "Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer"
}
,
{
"name" : "Piet Wigerinck",
"title" : "Member of the Executive Committee, Chief Scientific Officer"
}
,
{
"name" : "Elizabeth Goodwin",
"title" : "VP Corporate Communications \u0026 Investor Relations"
}
,
{
"name" : "Walid Abi-Saab",
"title" : "Member of the Executive Committee, Chief Medical Officer"
}
,
{
"name" : "Andre Hoekema",
"title" : "Member of the Executive Committee, Chief Business Officer"
}
,
{
"name" : "Rajesh Parekh",
"age" : "48",
"title" : "Non-Executive Chairman of the Board"
}
,
{
"name" : "Harrold van Barlingen",
"age" : "52",
"title" : "Non-Executive Director"
}
,
{
"name" : "Katrine Bosley",
"title" : "Independent Non-Executive Director"
}
,
{
"name" : "Werner Cautreels",
"age" : "65",
"title" : "Non-Executive Independent Director"
}
]
,"moreresources" : [
]
, "events" : [
{
"date": "Feb 23, 2018",
"time": "2:00PM GMT+1",
"future": 1,
"desc": "Q4 2017 Galapagos NV Earnings Call"
}
,
{
"date": "Feb 22, 2018",
"time": "10:00PM GMT+1",
"future": 1,
"desc": "Q4 2017 Galapagos NV Earnings Release"
}
,
{
"date": "Jan 8, 2018",
"time": "",
"future": 0,
"desc": "Galapagos NV at JPMorgan Healthcare Conference"
}
,
{
"date": "Dec 6, 2017",
"time": "",
"future": 0,
"desc": "Galapagos NV at Citi Global Healthcare Conference"
}
,
{
"date": "Nov 17, 2017",
"time": "",
"future": 0,
"desc": "Galapagos NV at Degroof Petercam Benelux Conference"
}
,
{
"date": "Nov 17, 2017",
"time": "",
"future": 0,
"desc": "Galapagos NV at Bryan Garnier Healthcare Conference"
}
,
{
"date": "Nov 15, 2017",
"time": "2:45PM GMT+1",
"future": 0,
"desc": "Galapagos NV at Stifel Healthcare Conference"
}
,
{
"date": "Nov 15, 2017",
"time": "",
"future": 0,
"desc": "Galapagos NV at Jefferies Global Healthcare Conference"
}
,
{
"date": "Nov 6, 2017",
"time": "",
"future": 0,
"desc": "Galapagos NV at Credit Suisse Healthcare Conference"
}
,
{
"date": "Nov 6, 2017",
"time": "",
"future": 0,
"desc": "Galapagos NV at EBD Group BioEurope Conference"
}
,
{
"date": "Nov 3, 2017",
"time": "1:00AM GMT+1",
"future": 0,
"desc": "Galapagos NV at NACFC 2017"
}
,
{
"webcasturl" : "https:\u002F\u002Fedge.media-server.com\u002Fm6\u002Fp\u002F7qo65go7",
"date": "Oct 27, 2017",
"time": "2:00PM GMT+2",
"future": 0,
"desc": "Q3 2017 Galapagos NV Earnings Call"
}
,
{
"date": "Oct 26, 2017",
"time": "10:00PM GMT+2",
"future": 0,
"desc": "Q3 2017 Galapagos NV Earnings Release"
}
]
}]